Share chart Pharmaron Beijing Co., Ltd.
About Pharmaron Beijing Co., Ltd.
Pharmaron Beijing Co., Ltd. вместе со своими дочерними компаниями предоставляет услуги в области фармацевтических исследований и разработок для отрасли наук о жизни в Северной Америке, Европе, материковом Китае, остальной части Азии и на международном уровне. Компания работает в пяти сегментах: Лабораторные услуги; Услуги в области химии, производства и контроля (CMC); Услуги по клиническому развитию; Биопрепараты и услуги клеточной и генной терапии; и другие. more detailsISIN | CNE100003PG4 |
---|---|
Industry | Biotechnology |
Sector | Health Care |
Валюта | hkd |
Валюта отчета | cny |
Див.доход ао | 5.46 |
Дивиденд ао | 0.2199 |
Сайт | https://www.pharmaron.com |
Цена ао | 15.6 |
Change price per day: | +0.5155% (15.52) |
---|---|
Change price per week: | -10.34% (17.4) |
Change price per month: | +11.43% (14) |
Change price per 3 month: | +13.37% (13.76) |
Change price per half year: | +75.68% (8.88) |
Change price per year: | +39.78% (11.16) |
Change price per 3 year: | -83.47% (94.4) |
Change price per 5 year: | -68.36% (49.3) |
Change price per 10 year: | 0% (15.6) |
Change price per year to date: | +11.75% (13.96) |
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
Institutions | Volume | Share, % |
---|---|---|
Vanguard International Stock Index-Emerging Markets Stk | 1463823 | 0.49 |
Vanguard International Stock Index-Total Intl Stock Indx | 1425870 | 0.47 |
DFA Emerging Markets Core Equity Portfolio | 831150 | 0.28 |
Schwab Strategic Tr-Schwab Emerging Markets Equity ETF | 413692 | 0.14 |
Fidelity Series Global Ex U.S. Index Fund | 317500 | 0.11 |
Vanguard Intl Equity Index Fds-FTSE All World ex U.S. Index Fund | 313827 | 0.1 |
DFA Emerging Markets Small Cap Series | 216700 | 0.07 |
DFA Emerging Markets Series | 156025 | 0.05 |
Dimensional ETF Tr-Dimensional Emerging Core Equity Market ETF | 143125 | 0.05 |
Vanguard Intl Equity Index - Total World Stock Index Fd | 116623 | 0.04 |
ETF | Share, % | Profitability for 1 year, % | Dividends, % |
---|---|---|---|
First Trust Emerging Markets Small Cap AlphaDEX Fund | 0.03467 | 1061.14 | 2.70393 |
![]() |
0.03 | -34.73 | |
Franklin FTSE China ETF | 0.01963 | 14.5 | 3.35323 |
Dimensional Emerging Markets Core Equity 2 ETF | 0.00694 | 15.96 | 3.34087 |
Franklin FTSE Asia ex Japan ETF | 0.006 | 14.43 | 2.66768 |
Dimensional World ex U.S. Core Equity 2 ETF | 0.00211 | 13.06 | 3.62488 |
![]() |
0.00209 | 17.02 | 3.40103 |
Avantis Emerging Markets Equity ETF | 0.00065 | 8.77 | 3.60513 |
Avantis Responsible Emerging Markets Equity ETF | 0.00058 | 17.6 | 3.1719 |
Vanguard ESG International Stock ETF | 0 | 6.39 | 3.07501 |
Head | Job title | Payment | Year of birth |
---|---|---|---|
Dr. Boliang Lou Ph.D. | Chairman & CEO | N/A | 1963 (62 years) |
Ms. Bei Zheng M.A, M.A. | Executive VP & Executive Director | N/A | 1967 (58 years) |
Mr. Shing Chung Li C.F.A., CPA | CFO & Secretary of the Board | N/A | 1978 (47 years) |
Dr. Hua Yang Ph.D. | Chief Scientific Officer & Deputy Manager | N/A | 1962 (63 years) |
Ms. Katherine Lee M.B.A., MBA | Chief Business Officer | N/A | |
Mr. Xiaoqiang Lou EMBA | Co-Founder, President, COO & Executive Director | 1968 (57 years) | |
Dr. Connie Sun Ph.D. | Senior VP & Global Head of Business Development of Small Molecules | ||
Ms. Celina Zhong M.B.A., MBA | Senior Vice President of Human Resources | ||
Mr. Stephen Lewinton | Senior Vice President of UK Operations | ||
Dr. Jingqi Huang | Senior Vice President of In Vivo Pharmacology |
Address: China, Beijing, Building 1 - open in Google maps, open in Yandex maps
Website: https://www.pharmaron.com
Website: https://www.pharmaron.com